-
Report details
-
55
Figures
-
121
Tables
-
Chapter 1: Executive Summary
-
Overview
-
Scope and Methodology
-
Market Overview and Potential
-
Coronavirus Cell and Gene Therapy Pipeline
-
Chapter 2: Introduction to Cell and Gene Therapy
-
Introduction
-
Cell Therapy
-
Gene Therapy
-
Viral Vector System and New Developments
-
Non-viral Systems for Transporting Genes
-
Gene Editing
-
Cell and Gene Therapy: Characteristics
-
Staffing
-
Manufacturing Process for CAR-T
-
Leukapheresis
-
Activation
-
Transduction
-
Expansion
-
Advancements and Barriers in Manufacturing Processes
-
Cost
-
Reimbursement
-
Logistics
-
Mergers and Acquisitions
-
Regulatory Developments
-
Fast Track
-
Orphan Drug
-
Breakthrough Therapy
-
Accelerated Approval
-
Priority Review
-
Individualized Gene Therapy Approval Process
-
Development and Pipeline Overview
-
Development Progress
-
Development by Condition/Disorder
-
Phase III Development
-
End User
-
Hospitals
-
Research Institutes
-
Wound Care Centers
-
Cancer Centers
-
Chapter 3: Cell and Gene Therapy Markets in Dermatology
-
Overview
-
Market Outlook
-
Principal Products
-
Apligraf
-
CureSkin
-
Dermagraft
-
Epicel
-
Gintuit
-
Grafix
-
Holoderm
-
Kaloderm
-
KeraHeal/KeraHeal-Allo
-
LaViv
-
Orcel
-
Quencell
-
RECELL
-
Rosmir
-
Stravix
-
TransCyte
-
Trends in Research and Development
-
Market Breakdown of Cell and Gene Therapies
-
Dermatology Cell and Gene Therapy Market by Indication
-
Regional Market Summary
-
Competitor Summary
-
Chapter 4: Cell and Gene Therapy Markets in Cardiovascular and Blood Disorders
-
Overview
-
Cardiovascular Disease
-
Selected Blood Disorders
-
Market Outlook
-
Principal Products
-
Collategene
-
Hearticellgram
-
HeartSheet
-
Neovasculgen
-
Stempeucel
-
Zynteglo
-
Cord Blood Products
-
Trends in Research and Development
-
Phase III Development
-
Orphan Drug, Fast Track, Breakthrough Designations
-
Market Breakdown of Cell and Gene Therapies
-
Cardiovascular and Blood Disorders Cell and Gene Therapy Market by Indication
-
Regional Market Summary
-
Competitor Summary
-
Chapter 5: Cell and Gene Therapy Markets in Oncology
-
Overview
-
Biochemistry of Cancer Cells
-
Causes of Cancer Growth
-
Environmental Factors, DNA, RNA
-
Cellular Oncogenes
-
Tumor Suppressor Genes
-
CAR-T Therapies
-
Global Cancer Burden
-
Market Outlook
-
Principal Products
-
APCeden
-
CreaVax-RCC
-
Gendicine
-
Imlygic
-
Immuncell-LC
-
Kymriah
-
Provenge
-
Yescarta
-
Zalmoxis
-
Trends in Research and Development
-
Phase III Development
-
Orphan Drug, Fast Track, Breakthrough Designations
-
Market Breakdown of Cell and Gene Therapies
-
Oncology Cell and Gene Therapy Market by Cancer Type
-
Regional Market Summary
-
Competitor Summary
-
Chapter 6: Cell and Gene Therapy Markets in Ophthalmic Conditions
-
Overview
-
Market Outlook
-
Principal Products
-
Trends in Research and Development
-
Phase III Development
-
Orphan Drug, Fast Track, Breakthrough Designations
-
Market Breakdown of Cell and Gene Therapies
-
Regional Market Summary
-
Competitor Summary
-
Chapter 7: Cell and Gene Therapy Markets in Musculoskeletal Conditions and Disor…
-
Overview
-
Market Outlook
-
Principal Products
-
AlloStem
-
BIO4
-
Carticel
-
Cartiform
-
CartiLife
-
Cartistem
-
ChondroCelect
-
Chondron
-
JACC
-
MACI
-
Ortho-ACI and Ortho-ATI
-
Ossron
-
Osteocel and Osteoplus
-
Spherox
-
Trinity Elite and Trinity Evolution
-
Trends in Research and Development
-
Market Breakdown of Cell Therapies
-
Musculoskeletal Cell Therapy Market by Indication
-
Regional Market Summary
-
Competitor Summary
-
Chapter 8: Cell and Gene Therapy Markets in Other Conditions
-
Overview
-
Market Outlook
-
Principal Products
-
Alofisel
-
Cupistem
-
Givlaari
-
Glybera
-
NeuroNata-R
-
Onpattro
-
Stemirac
-
Strimvelis
-
Temcell/Prochymal
-
Zolgensma
-
Trends in Research and Development
-
Market Breakdown of Cell and Gene Therapies
-
Regional Market Summary
-
Competitor Summary
-
Chapter 9: Cell and Gene Therapy Market Review
-
Market Influences
-
Global Demographics
-
Cost Containment
-
Global Market Summary
-
Cell vs. Gene Therapy Markets
-
Regional Market Overview
-
United States
-
Europe/European Union
-
Other Countries
-
Competitor Ranking in Cell and Gene Therapy Markets
-
Chapter 10: Market Participants
-
Leading Influencers
-
Advantagene, Inc.
-
Advaxis, Inc.
-
AlloSource
-
Alnylam Pharmaceuticals
-
Amgen
-
AnGes Inc.
-
Anterogen Co Ltd.
-
Atara Biotherapeutics
-
Athersys, Inc
-
AveXis, Inc.
-
BioCardia
-
Biogen, Inc.
-
BioMarin Pharmaceuticals
-
Company Summary
-
Products
-
bluebird bio, Inc.
-
Company Summary
-
Products
-
Brainstorm Cell Therapeutics
-
Caladrius Biosciences
-
Celyad
-
Cook Myosite, Inc
-
Cytori Therapeutics, Inc
-
Dendreon Pharmaceuticals LLC
-
Ferring Pharmaceuticals
-
Fibrocell (Castle Creek Biosciences)
-
Gamida Cell Ltd.
-
GenSight Biologics S.A.
-
Gilead Sciences, Inc.
-
Gradalis, Inc
-
Inovio Pharmaceuticals, Inc.
-
Kiadis Pharma B.V.
-
Medeor Therapeutics
-
Medipost Co, Ltd.
-
Merck & Co., Inc.
-
Mesoblast Ltd.
-
Moderna, Inc
-
Neurotech Pharmaceuticals, Inc.
-
Northwest Biotherapeutics, Inc.
-
Novartis AG
-
NuVasive Biologics
-
Orchard Therapeutics
-
Organogenesis
-
Orthofix Medical Inc.
-
Osiris Therapeutics, Inc.
-
Pharmicell
-
Pluristem Therapeutics, Inc.
-
Quark Pharmaceuticals
-
Regenerative Medical System
-
Renova Therapeutics
-
Sangamo Therapeutics
-
Sanofi
-
SOTIO a.s.
-
Spark Therapeutics
-
Tessa Therapeutics, Ltd.
-
Tocagen, Inc.
-
uniQure N.V.
-
VBL Therapeutics (Vascular Biogenics Ltd.)
-
Vericel Corporation
-
ViroMed Co Ltd (Helixmith)
|
Cell Therapy and Gene Therapy Markets
27 Apr 2020
This is an exciting and interesting time in the cell and gene therapy industry. The science is moving ahead as industry industrializes and standardizes the manufacturing and commercialization of products. Cell and gene therapy products are transforming the treatment of cancers and genetic diseases, as well as expanding into other areas of medicine including autoimmune diseases, cardiovascular diseases, musculoskeletal disease, dermatological diseases, and many others. Cell Therapy and Gene Therapy Markets presents the market in segments that provide an overview of disease epidemiology, market estimates and forecasts, and competitive summary of leading providers:
- Cell and Gene Therapy Market Summary by Product Segment, 2020-2030 ($ millions) (Dermatological, Cardiovascular - Blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions, Total Market)
- Cell and Gene Therapy Market Summary by Method, 2020-2030 ($ millions) (Cell Therapy, Gene Therapy, Total Market)
- Cell and Gene Therapy Market Summary by Geographical Region, 2020-2030 ($ millions) (United States, Europe/European Union, Other Countries, Global Market)
- Cell and Gene Therapy Market Summary for United States by Product Segment, 2020-2030 ($ millions) (Dermatological, Cardiovascular - Blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions, Total)
- U.S. Cell and Gene Therapy Market, Distribution by Product Segment (Dermatological, Cardiovascular-blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions), 2020 (%)
- Europe Cell and Gene Therapy Market, Distribution by Product Segment (Dermatological, Cardiovascular-blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions), 2020 (%)
- Other Countries Cell and Gene Therapy Market, Distribution by Product Segment (Dermatological, Cardiovascular-blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions), 2020 (%)
- Estimated Cell and Gene Therapy Sales by Leading Competitor, 2019 Sales ($ millions)
The report examines developments in cell and gene therapy markets by condition/disorder, including principal products, trends in research and development, market breakdown of cell and gene therapies, regional market summary, and competitor summary. The following conditions/disorders are covered:
- Dermatology, including:
- Dermatology Cell and Gene Therapy Markets by Product Type, Estimated 2020 and Projected 2025 and 2030 ($ millions) (Stem cells, Skin cells)
- Dermatology Cell and Gene Therapy Market by General Indication, Estimated 2020, Projected 2025 and 2030 ($ millions) (Wound healing/treatment, Other indications [wrinkles, scar treatment])
- Dermatology Cell and Gene Therapy Market by Country/Region, Estimated 2020, Projected 2025 and 2030 ($ millions) (United States, Europe/European Union, S. Korea, Other countries)
- Dermatology Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2019 ($ millions)
- Cardiovascular and Blood Disorders, including:
- Cardiovascular and Blood Disorders Cell and Gene Therapy Markets by Product Type, Estimated 2020 and Projected 2025 and 2030 ($ millions) (Stem cells, Gene therapy, Other cell therapies; Stromal cells)
- Cardiovascular and Blood Disorders Cell and Gene Therapy Market by General Indication, Estimated 2020, Projected 2025 and 2030 ($ millions) (Cardiac disorders, Vascular disorders, Blood disorders, Hypercholesterolemia)
- Cardiovascular and Blood Disorders Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2020 and Projected 2025, 2030 ($ millions) (United States, Europe, S. Korea, Japan, ROW)
- Oncology, including:
- Oncology Cell and Gene Therapy Markets by Product Type, Estimated 2020 and Projected 2025 and 2030 ($ millions) (CAR-T, Cell immunotherapy, Gene therapy, Other cell therapy)
- Oncology Cell and Gene Therapy Market by General Indication, Estimated 2020, Projected 2025 and 2030 ($ millions) (Blood cancers, Prostate cancer, Melanoma, Other cancers)
- Oncology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2020 and Projected 2025, 2030 ($ millions) (United States, Europe, ROW)
- Oncology Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2019 ($ millions)
- Ophthalmic Conditions, including:
- Ophthalmology Cell and Gene Therapy Markets by Product Type, Estimated 2020 and Projected 2025 and 2030 ($ millions) (Stem cells, Gene therapy, Other cell therapy)
- Ophthalmology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2020 and Projected 2025, 2030 ($ millions) (United States, Europe, Other countries)
- Musculoskeletal Conditions and Disorders, including:
- Musculoskeletal Cell Therapy Market, Estimated 2020 and Projected 2025 and 2030 ($ millions)
- Musculoskeletal Cell and Gene Therapy Market by General Indication, Estimated 2020, Projected 2025 and 2030 ($ millions) (Cartilage Defect/Damage Repair, Bone Defect/Damage Repair, Others [tendon damage, osteoarthritis])
- Musculoskeletal Cell and Gene Therapy Market by Country/Region, Estimated 2020, Projected 2025 and 2030 ($ millions) (United States, Europe/European Union, S. Korea, Other countries)
- Musculoskeletal Cell Therapy Competitor Market Share, Reported and Estimated 2019 ($ millions)
- Other Conditions, including:
- Other Conditions Cell and Gene Therapy Markets by Product Type, Estimated 2020 and Projected 2025 and 2030 ($ millions) (Cell therapy, Gene therapy, Gene-modified cell therapy)
- Other Conditions Cell and Gene Therapy Market by Country/Region, Estimated 2020, Projected 2025 and 2030 ($ millions) (United States, Europe/European Union, S. Korea, Other countries)
Cell Therapy and Gene Therapy Markets also includes several discussions on cell and gene therapies in development and the impact these are expected to have on the market. Throughout the report, several market indicators, trends, and barriers are discussed. The report comments on the current COVID-19 cell and gene therapy pipeline. There are a number of companies that are responding to the call to develop a therapeutic or vaccine for the coronavirus, including:
- Vitro Biopharma
- Celularity and Sorrento Therapeutics
- CanSino Biologics
- Mesoblast
- Acturus Therapeutics
- Entos Pharmaceuticals
- Zydus Cadila
- AlloVir and Baylor College of Medicine
- Athersys
- Exothera
- Sirnaomics
- Mesoblast
The leading influencers in the market are those which have become first-to-market participants in the cell and gene therapy segment, have new developments which may disrupt current market conditions, and/or have an extensive pipeline sure to impact the market in the long-term forecast:
- Advantagene
- Advaxis
- AlloSource
- Alnylam Pharmaceuticals
- Amgen
- AnGes USA
- Anterogen
- Atara Therapeutics
- Athersys
- AveXis
- BioCardia
- BioMarin Pharmaceuticals
- Bluebird bio
- BrainStorm Cell Therapeutics
- Caladrius Bioscience
- Celyad
- Cook MyoSite
- Cytori Therapeutics
- Dendreon
- Ferring Pharmaceuticals
- Fibrocell
- Gamida Cell
- GenSight Biologics
- Genzyme
- Gilead Sciences
- Gradalis
- Inovio Pharmaceuticals
- Kiadis Pharma
- Medeor Therapeutics
- Medipost
- Merck
- Mesoblast
- MolMed
- Neurotech USA
- Nightstar Therapeutics
- Northwest Biotherapeutics
- Novartis
- NuVasive
- Orchard Therapeutics
- Organogenesis
- Orthofix
- Osiris Therapeutics (part of Smith & Nephew)
- Pharmicell
- Pluristem Therapeutics
- Quark Pharmaceuticals
- Renova Therapeutics
- Sanofi Pasteur
- SOTIO
- Spark Therapeutics
- Tessa Therapeutics
- Tocagen
- uniQure
- VBL Therapeutics
- ViroMed
Because gene therapies are currently not available in any wide capacity, there is little precedent upon which to base forecasts. Dollar figures represent the estimated global market for 2019 and expected market for 2020 based on first quarter company reports and is expressed in current dollars. Forecasts are provided through 2025 and an extended forecast for 2030. The size of each market segment refers to manufacturers’ revenues.
Page Count: 247
Table of Contents
-
Chapter 1: Executive Summary
-
Overview
-
Scope and Methodology
-
Market Overview and Potential
-
Coronavirus Cell and Gene Therapy Pipeline
-
Chapter 2: Introduction to Cell and Gene Therapy
-
Introduction
-
Cell Therapy
-
Gene Therapy
-
Viral Vector System and New Developments
-
Non-viral Systems for Transporting Genes
-
Gene Editing
-
Cell and Gene Therapy: Characteristics
-
Staffing
-
Manufacturing Process for CAR-T
-
Leukapheresis
-
Activation
-
Transduction
-
Expansion
-
Advancements and Barriers in Manufacturing Processes
-
Cost
-
Reimbursement
-
Logistics
-
Mergers and Acquisitions
-
Regulatory Developments
-
Fast Track
-
Orphan Drug
-
Breakthrough Therapy
-
Accelerated Approval
-
Priority Review
-
Individualized Gene Therapy Approval Process
-
Development and Pipeline Overview
-
Development Progress
-
Development by Condition/Disorder
-
Phase III Development
-
End User
-
Hospitals
-
Research Institutes
-
Wound Care Centers
-
Cancer Centers
-
Chapter 3: Cell and Gene Therapy Markets in Dermatology
-
Overview
-
Market Outlook
-
Principal Products
-
Apligraf
-
CureSkin
-
Dermagraft
-
Epicel
-
Gintuit
-
Grafix
-
Holoderm
-
Kaloderm
-
KeraHeal/KeraHeal-Allo
-
LaViv
-
Orcel
-
Quencell
-
RECELL
-
Rosmir
-
Stravix
-
TransCyte
-
Trends in Research and Development
-
Market Breakdown of Cell and Gene Therapies
-
Dermatology Cell and Gene Therapy Market by Indication
-
Regional Market Summary
-
Competitor Summary
-
Chapter 4: Cell and Gene Therapy Markets in Cardiovascular and Blood Disorders
-
Overview
-
Cardiovascular Disease
-
Selected Blood Disorders
-
Market Outlook
-
Principal Products
-
Collategene
-
Hearticellgram
-
HeartSheet
-
Neovasculgen
-
Stempeucel
-
Zynteglo
-
Cord Blood Products
-
Trends in Research and Development
-
Phase III Development
-
Orphan Drug, Fast Track, Breakthrough Designations
-
Market Breakdown of Cell and Gene Therapies
-
Cardiovascular and Blood Disorders Cell and Gene Therapy Market by Indication
-
Regional Market Summary
-
Competitor Summary
-
Chapter 5: Cell and Gene Therapy Markets in Oncology
-
Overview
-
Biochemistry of Cancer Cells
-
Causes of Cancer Growth
-
Environmental Factors, DNA, RNA
-
Cellular Oncogenes
-
Tumor Suppressor Genes
-
CAR-T Therapies
-
Global Cancer Burden
-
Market Outlook
-
Principal Products
-
APCeden
-
CreaVax-RCC
-
Gendicine
-
Imlygic
-
Immuncell-LC
-
Kymriah
-
Provenge
-
Yescarta
-
Zalmoxis
-
Trends in Research and Development
-
Phase III Development
-
Orphan Drug, Fast Track, Breakthrough Designations
-
Market Breakdown of Cell and Gene Therapies
-
Oncology Cell and Gene Therapy Market by Cancer Type
-
Regional Market Summary
-
Competitor Summary
-
Chapter 6: Cell and Gene Therapy Markets in Ophthalmic Conditions
-
Overview
-
Market Outlook
-
Principal Products
-
Trends in Research and Development
-
Phase III Development
-
Orphan Drug, Fast Track, Breakthrough Designations
-
Market Breakdown of Cell and Gene Therapies
-
Regional Market Summary
-
Competitor Summary
-
Chapter 7: Cell and Gene Therapy Markets in Musculoskeletal Conditions and Disorders
-
Overview
-
Market Outlook
-
Principal Products
-
AlloStem
-
BIO4
-
Carticel
-
Cartiform
-
CartiLife
-
Cartistem
-
ChondroCelect
-
Chondron
-
JACC
-
MACI
-
Ortho-ACI and Ortho-ATI
-
Ossron
-
Osteocel and Osteoplus
-
Spherox
-
Trinity Elite and Trinity Evolution
-
Trends in Research and Development
-
Market Breakdown of Cell Therapies
-
Musculoskeletal Cell Therapy Market by Indication
-
Regional Market Summary
-
Competitor Summary
-
Chapter 8: Cell and Gene Therapy Markets in Other Conditions
-
Overview
-
Market Outlook
-
Principal Products
-
Alofisel
-
Cupistem
-
Givlaari
-
Glybera
-
NeuroNata-R
-
Onpattro
-
Stemirac
-
Strimvelis
-
Temcell/Prochymal
-
Zolgensma
-
Trends in Research and Development
-
Market Breakdown of Cell and Gene Therapies
-
Regional Market Summary
-
Competitor Summary
-
Chapter 9: Cell and Gene Therapy Market Review
-
Market Influences
-
Global Demographics
-
Cost Containment
-
Global Market Summary
-
Cell vs. Gene Therapy Markets
-
Regional Market Overview
-
United States
-
Europe/European Union
-
Other Countries
-
Competitor Ranking in Cell and Gene Therapy Markets
-
Chapter 10: Market Participants
-
Leading Influencers
-
Advantagene, Inc.
-
Advaxis, Inc.
-
AlloSource
-
Alnylam Pharmaceuticals
-
Amgen
-
AnGes Inc.
-
Anterogen Co Ltd.
-
Atara Biotherapeutics
-
Athersys, Inc
-
AveXis, Inc.
-
BioCardia
-
Biogen, Inc.
-
BioMarin Pharmaceuticals
-
Company Summary
-
Products
-
bluebird bio, Inc.
-
Company Summary
-
Products
-
Brainstorm Cell Therapeutics
-
Caladrius Biosciences
-
Celyad
-
Cook Myosite, Inc
-
Cytori Therapeutics, Inc
-
Dendreon Pharmaceuticals LLC
-
Ferring Pharmaceuticals
-
Fibrocell (Castle Creek Biosciences)
-
Gamida Cell Ltd.
-
GenSight Biologics S.A.
-
Gilead Sciences, Inc.
-
Gradalis, Inc
-
Inovio Pharmaceuticals, Inc.
-
Kiadis Pharma B.V.
-
Medeor Therapeutics
-
Medipost Co, Ltd.
-
Merck & Co., Inc.
-
Mesoblast Ltd.
-
Moderna, Inc
-
Neurotech Pharmaceuticals, Inc.
-
Northwest Biotherapeutics, Inc.
-
Novartis AG
-
NuVasive Biologics
-
Orchard Therapeutics
-
Organogenesis
-
Orthofix Medical Inc.
-
Osiris Therapeutics, Inc.
-
Pharmicell
-
Pluristem Therapeutics, Inc.
-
Quark Pharmaceuticals
-
Regenerative Medical System
-
Renova Therapeutics
-
Sangamo Therapeutics
-
Sanofi
-
SOTIO a.s.
-
Spark Therapeutics
-
Tessa Therapeutics, Ltd.
-
Tocagen, Inc.
-
uniQure N.V.
-
VBL Therapeutics (Vascular Biogenics Ltd.)
-
Vericel Corporation
-
ViroMed Co Ltd (Helixmith)
|
Market size, forecast and pipeline review for major cell therapy and gene therapy products. Development deals and litigation discussed. Corporate profiles provided for top companies. Market forecasts to 2027.
More information about this product
Other Users Also Viewed
26 Aug 2020
What is the Size of IVD Market Segments? Who’s Winning? Who’s Merged? Who’s Launched Game-Changing Products?
One book definitively answers these questions, from a publisher that is focused on in vitro diagnostics. Now in its 13th edition, this…
|